meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - adjuvant
13
antibody–drug conjugate
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus endocrine therapy
palbociclib based treatment
palbociclib
palbociclib plus endocrine therapy
ribociclib based treatment
HER inhibitor
HER2 inhibitor
neratinib based treatment
neratinib
pertuzumab based treatment
pertuzumab plus trastuzumab
trastuzumab based treatment
docetaxel plus carboplatin with trastuzumab followed by trastuzumab
doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
pembrolizumab based treatment
pembrolizumab alone
mTOR inhibitors
everolimus
poly ADP-ribose polymerase (PARP) inhibitor
olaparib
versus all
vs chemotherapy
vs doxorubicin plus cyclophosphamide followed by docetaxel
vs Standard of Care (SoC)
vs endocrine therapy
vs HER inhibitor
vs HER2 inhibitor
vs trastuzumab based treatment
vs docetaxel plus carboplatin with trastuzumab followed by trastuzumab
vs trastuzumab
vs non active control
vs no additional treatment
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network